- Towards rational design of AMPA receptor ligands: an integrated medicinal, computational, biostructural and molecular pharmacological approach (A. Hogner, et al.).
- From heparin to synthetic antithrombotics. The pentasaccharide story and follow up (C.C.A. van Boeckel).
- A new future for synthesis? (A. Bruggink).
- Directed evolution of enantioselective enzymes as catalysts in the production of chiral pharmaceuticals (M.T. Reetz).
- At the interface of organic synthesis and biosynthesis (R. Schoevaart, A.P.G. Kieboom).
- What can structure tell us about function in the estrogen receptors? (R.E. Hubbart).
- Molecular docking and dynamics simulations in the ligand binding domain of steroid hormone receptors (M. Kouwijzer, J. Mestres).
- Peroxisome proliferator-activated receptors and reverse endocrinology (S. Kliewer).
- Biomolecular mass spectrometry related to drug research (A.J.R. Heck, C.S. Maier).
- Chemical and biological diversity in drug discovery (P. Angeli, G. Gaviraghi).
- Muscarine acetylcholine receptor knockout mice: phenotypical analysis and clinical implications (J. Gomeza, et al.).
- Changes in expression of the orphan G-protein coupled receptor GPR7 in human painful peripheral neuropathies (P.F. Zaratin, et al.).
- Computational methods for the analysis of molecular diversity (V.J. Gillet, P. Willett).
- Enhancing drug discovery by acquisition of chemical diversity (D. Langley).
- Chemical diversity as a driving force to design and put in practice synthetic strategies leading to combinatorial libraries for lead discovery and lead optimization (P. Seneci).
- Beyond G proteins: the role of accessory proteins in G protein-coupled receptor signalling (H. Just, et al.).
- Mechanisms of action of antipsychotic drugs: the role of inverse agonism at the D2 dopamine receptor (Ph.G. Strange).
- Agonist channeling of &agr;2-adrenoceptor function (K.E.O. Åkerman, et al.).
- Antibacterials as wonder drugs and how their effectiveness is being compromised (D. Golemi, et al.).
- Pseudomonas aeruginosa quorum sensing: a target for antipathogenic drug discovery (E.P. Greenberg).
- Discovery and development of new anti-bacterial drugs (I. Chopra, L. Hesse, A. O'Neill).
- Discovery of small molecule insulin mimetics as potential novel antidiabetic agents (B.B. Zhang).
- Expression databases for pharmaceutical lead optimisation (L.M. Furness).
- New developments in the pharmacology of cannabinoids (R.G. Pertwee). Author index. Subject index.
The tradition of setting new trends in medicinal chemistry continued at the 13th Symposium where topics included chemical and biological diversity, new paradigms in drug action, and new insights in receptor mechanisms. Other topics of great interest discussed, and included in these proceedings, are the discoveries in green chemistry, the interface between organic synthesis and biosynthesis, the growing problem of resistant micro-organisms and the possibilities to identify new, and better, antibiotics. And finally, in recent developments, the discovery of small molecules with insulin sensitizing properties.
For clinical pharmacologists, pharmaceutics and toxicologists
- No. of pages:
- © Elsevier Science 2002
- 25th January 2002
- Elsevier Science
- eBook ISBN:
Department of Pharmacochemistry, Vrije Universiteit, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands